tbuckley/cabot-search huggingface dataset:
Iron inhibits the cytotoxicity of nitric oxide and the associated cytolysis by natural killer cells of MCF-7 human breast cancer cells
Authors: Xianpeng Jiang, Ken Hsu, Jonathan F. Head, Robert L. Elliott
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

629 

Natural killer (NK) cells and nitric oxide (NO) are both important components of the natural or innate immune response. Natural killer (NK) cell cytolysis is associated with synthesis of NO, and this NO can affect cellular iron metabolism. Iron has been reported to promote carcinogenesis and neoplastic cell growth. In the present study, we investigated the role of iron in NO-mediated cytotoxicity and NK cell cytolysis. MCF-7 breast cancer cells were treated with S-nitroso-N-acetyl- penicillamine (SNAP), a NO donor, or SNAP plus ferric chloride. MCF-7 cells and NK-92MI human NK cells were co-incubated for 4 hours in media in the absence or presence of ferric chloride. Cell proliferation was determined by 3[H]-thymidine incorporation. NK-92MI lysis of MCF-7 cells was assessed with a 51Cr-release assay. NO concentration was measured with the Griess Reagent System. Cell transferrin receptor, ferritin and intracellular iron were also quantatively measured. We found that SNAP significantly suppressed the growth of MCF-7 breast cancer cells in a dose-dependent manner (IC50 of 50μm, 3 days of incubation). NO up-regulated the expression of the transferrin receptor and depleted intracellular iron in MCF-7 cells. The addition of ferric chloride significantly decreased the SNAP-induced cytotoxicity to the MCF-7 breast cancer cells. The 51Cr-release assay showed that NK-92MI cells lysed MCF-7 cells (10.9+4.5% and 5.0+1.8% specific lysis of MCF-7 cells at NK-92MI to MCF-7 ratios of 10:1 and 2.5:1, respectively). Exogenous 400μm of FeCl3 significantly decreased the cytotoxic activity with 7.5+4.4% (p<0.05) and 2.0+2.1% (p<0.05) specific lysis at NK-92MI to MCF-7 ratios of 10:1 and 2.5:1, respectively. Nitrite, a stable and nonvolatile breakdown products of NO, was also found in the NK-92MI culture supernatants. The concentration of nitrite was dramatically increased when the MCF-7 target cells were co-incubated with the NK-92MI cells, and the formation of NO by NK-92MI was not inhibited by the addition of iron. We conclude that one mechanism of NO-mediated cytotoxicity is by depletion of intracellular iron, and NK-92MI cytolysis is associated with the production of NO. Therefore, iron not only protects tumor cells from exogenous NO cytotoxicity, but also prevent NK cells cytolysis of tumor cells by inhibiting the cytotoxicity of the NO produced by the NK cells. This is the first time that iron has been shown to decrease NK cell cytolysis of tumor cells.
Psychiatric standards in driver licensing
Authors: R. Shlensky
Journal: JAMA (1976)

THERE are 130 million cars on the road in the United States, and each year in the early 1970s, there were 48,000 fatal accidents, in which 55,000 people were killed.<sup>1</sup>Two million more people were disabled annually, and an inestimable amount of property was destroyed or damaged. We know that some of these deaths are intended suicides, and it is likely that many more are unconsciously motivated self-destructive acts. Undoubtedly, many accidents have some less definitive relationship to the emotional state of the drivers involved. The states have a constitutionally ordained police power to regulate the public safety and health. Everyone has a right to be as free as possible from the threat of sudden death or mutilation, and the states have the responsibility to restrict the licensing of automobile drivers to this end. On the other hand, driving privileges profoundly affect the quality of life in our society.
Abstract 18388: Albuminuria Determines Event-Free Survival in Atherosclerotic Renal-Artery Stenosis
Authors: Wencan He, Kaleigh L Evans, Kaili Ren, David A Folt, Pamela S Brewster, Timothy P Murphy, Donald E Cutlip, Lance D Dworkin, Joseph I Shapiro, William Henrich, Christopher J Cooper, Michael Steffes, Michael R Jaff
Journal: Circulation (2014)

Introduction: Stenosis severity and revascularization may have little relation to outcomes in patients with atherosclerotic renal artery stenosis (ARAS). Albuminuria is a direct indicator of glomerular injury and kidney health. The effect of albuminuria on survival in people with ARAS is not well characterized. Hypothesis: Proteinuria predicts clinical events in people with ARAS. Methods: The Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) clinical trial is a prospective trial of individuals with ARAS. Patients were followed to a maximum of 8 years. Urine albumin and creatinine were measured at a single core lab and the ratio was log transformed (LUACR). The composite endpoint included: cardiovascular (CV) or renal mortality, myocardial infarction (MI), stroke, chronic heart failure (CHF), progressive renal insufficiency (PRI), and renal replacement therapy (RRT). Utilizing receiver operating characteristic (ROC) curves, we developed 3 cutoff points for the LUACR using three methods: Youden’s, closest to the top-left point and the sample median. In order to verify the cutoff point we randomly divided the sample into a training set and a verification set of equal size. Cross verification was applied and the simulation was repeated 5000 times. The analyses are controlled by age, gender, cystatin-c, and systolic blood pressure. Results: Cross verification shows that Youden’s method gives the highest specificity and accuracy. It yields an optimal cutoff point of LUACR=3.83 (UACR is exp(3.83)=46.06). Subjects with values above this threshold, in the verification sample, had higher rates of the composite event rate (50% vs. 27%), PRI (27% vs. 13%), and CHF (16% vs. 5%), all p&lt;0.001; CV death (13% vs. 7%), and all-cause mortality (14% vs. 7%), both p&lt;0.01. Conclusions: Albuminuria powerfully predicts adverse cardiovascular and renal events, including all-cause mortality, in people with ARAS.
Abstract P5-04-10: Characterization of the immune infiltrate in HER2+ breast cancer
Authors: Shridar Ganesan, Gabriela Alexe, Kim M Hirshfield, Ming Yao, Gyan Bhanot, Toppmeyer Deborah
Journal: Cancer Research (2015)

Abstract A subset of HER2+ breast cancer is characterized by high expression of lymphocyte-associated genes and the presence of a robust, histologically apparent, lymphocytic infiltrate. The presence of an immune signature and lymphocytic infiltration is associated with improved outcome, and may be a marker of improved response to trastuzumab-based therapy. The relationship of the immune signature in these cancers to the biology and functional status of the lymphocyte subsets present in the tumor microenvironment remain unclear. To better characterize the immune microenvironment of HER2+ cancers, we have analyzed paired RNA sequencing data and histologic image data from The Cancer Genome Atlas. We have confirmed the presence of a strong immune signature in a subset of HER2+ breast cancers that is correlated with the presence of a robust lymphocytic infiltrate. Immuno-phenotyping of the lymphocytic infiltrate was performed on an independent set of HER2+ breast cancers from the Rutgers Cancer Institute of New Jersey. CD8+ T-cells and macrophages are a significant component of the immune infiltrate in these cancers. Interestingly, CD20+ B-cells were also present in the tumor stroma as large aggregates whose organization is suggestive of the presence of ectopic germinal centers. The relationship of lymphocyte subsets present in HER2+ breast cancer, immunoglobulin subtypes expressed and correlation with immune checkpoint protein expression will be presented. The composition of the immune infiltrate and its organization into ectopic germinal centers may give new insight into the role of the immune microenvironment in the development of HER2+ breast cancer and the response to trastuzumab. Citation Format: Shridar Ganesan, Gabriela Alexe, Kim M Hirshfield, Ming Yao, Gyan Bhanot, Toppmeyer Deborah. Characterization of the immune infiltrate in HER2+ breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P5-04-10.
Promoting Adequate Sleep Finds a Place on the Public Health Agenda
Authors: Lynne Lamberg
Journal: JAMA (2004)

BETHESDA, MD—After days of prisonerof-war simulations that involved sleep deprivation, young US Army Special Forces soldiers had trouble thinking, multitasking, and hitting targets accurately. Asked if they could continue the grueling routine, however, all claimed, “Good to go, sir!” “Senior officers told us sleep is a sign of weakness,” recalled one of those soldiers, now US Surgeon General Richard H. Carmona, MD, MPH. The same attitude pervaded his training as a surgeon 25 years ago, Carmona said. It persists today, increasing the risk of medical errors . Regulations limiting residents to 80 work hours per week that went into effect last July, he said, in some places are “still being circumvented and ignored, especially in surgery.” Chronic sleep loss and untreated sleep disorders harm the health and quality of life of 70 million individuals in the United States, Carmona noted. Sleep problems cost the nation $15 billion in health care expenses and $50 billion in lost productivity annually, he said at a sleep conference at the National Institutes of Health in March. The two-day meeting, sponsored by the National Center on Sleep Disorders Research (NCSDR), sought to identify sleep knowledge now “good to go” to primary care physicians and the general public, and to craft action plans to disseminate that information widely. The National Center on Sleep Disorders Research aims to boost recognition and treatment of sleep disorders, cut health care costs arising from untreated sleep disorders, and enhance public health and quality of life. More than two dozen speakers summarized state-of-the-art findings pertaining to many of the more than 80 disorders of sleep or the sleep/wake
Abstract 1619: Prevalence And Clinical Significance Of Right Precordial T-wave Inversion At Electrocardiographic Preparticipation Screening: A Prospective Study On 3086 Young Competitive Athletes
Authors: Domenico Corrado, Pierantonio Michieli, Maurizio Schiavon, Barbara Bauce, Cristina Basso, Andrea Nava, Gaetano Thiene
Journal: Circulation (2007)

Background: T-wave inversion in right precordial leads (beyond V1) is usually dismissed in young people as non-specific or as persistence of the juvenile T-wave pattern. However, such a pattern is ...
Oral immunotherapy with immunodominant T‐cell epitope peptides alleviates allergic reactions in a Balb/c mouse model of egg allergy
Authors: P. Rupa, Y. Mine
Journal: Allergy (2011)

To cite this article: Rupa P, Mine Y. Oral immunotherapy with immunodominant T‐cell epitope peptides alleviates allergic reactions in a Balb/c mouse model of egg allergy. Allergy 2012; 67 : 74–82. Abstract Background: Allergen‐specific T‐cell epitopes are obvious targets for immunotherapeutic interventions in allergic disease. T‐cell epitope peptides given orally may provide a practical way of inducing tolerance and preventing allergy. Objective: This study investigates oral immunotherapy (OIT) with T‐cell epitope peptides of the dominant egg‐white allergen ovomucoid (Ovm) in a Balb/c mouse model of egg allergy. Methods: Groups of mice were orally sensitized to Ovm and subsequently administered Ovm T‐cell epitopes [single peptide 157–171 (SP) or multiple peptide (157–171) 3 (MP)], followed by oral challenge with Ovm. Outcomes post oral challenge were measured as clinical signs, serum histamine, antibody activity (IgG, IgE, IgG1, IgG2, IgA), cytokines (IL‐4, IFN‐γ, IL‐12p70, IL‐10, TGF‐β, and IL‐17), and T regulatory cells (Tregs). Results: Clinical signs were less frequent in both SP and MP groups ( P ≤ 0.05). Specific IgE was less and IgA was more in both groups; however, SP‐treated mice had less histamine and IgG1 and more IgG2‐related antibodies indicating a bias toward the type‐1 response ( P ≤ 0.05). Concentration of type‐2 cytokine interleukin‐4 (IL‐4) was significantly less in both groups and IL‐12p70 and IL‐10 were more in SP‐treated mice ( P ≤ 0.001). Interferon‐γ, IL‐17, and TGF‐β did not differ significantly. There was significant increase in the percentage of CD4+FOXP3+ and CD4+CD25+ cells in the SP group, indicating the significant role of Tregs in immune regulation. Conclusion: In summary, we demonstrated that OIT with SP and MP comprising the immunodominant regions of Ovm was safe and significantly reduced subsequent frequency of allergy to Ovm, and validated potential use of Ovm T‐cell epitope as an immunoregulator.
WHO Meeting Targets Global Concerns
Authors: H David Banta
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 16428: Subclinical Atherosclerosis and Obesity Phenotypes in Mexican Americans
Authors: Susan T Laing, Beverly Smulevitz, Kristina P Vatcheva, David D McPherson, Joseph B McCormick, Susan P Fisher-Hoch
Journal: Circulation (2014)

Despite a robust association between carotid intima-media thickness (cIMT) and cardiovascular disease (CVD), the influence of obesity on subclinical atherosclerosis is not well understood and data are inconsistent. This may be related to varying cardiometabolic risk among obese individuals. Data on CVD in Mexican Americans are likewise conflicting and despite elevated obesity prevalence, reported death rates are no higher than Whites. We hypothesize that cardiometabolic risk modulates the obesity effect on early atherosclerosis development in Mexican Americans and that the influence of cardiometabolic risk is more important than body mass index (BMI) alone. METHODS: Participants (n=493) were drawn from the Cameron County Hispanic Cohort, a Mexican American cohort in Texas on the US-Mexico border. Metabolic health was defined as having < 2 of the following cardiometabolic abnormalities: BP ≥ 130/85; triglyceride ≥ 150 mg/dL; high-density lipoprotein cholesterol <40 mg/dL (men) or <50 mg/dL (women); fasting...
Handbuch der Sexualwissenschaften mit besonderer Berücksichtigung der kulturgeschichtlichen Beziehungen.
Authors: Albert Moll, Georg Buschan
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 13079: Variation in Laboratory Monitoring After Initiation of a Mineralocorticoid Receptor Antagonist in Patients With Heart Failure
Authors: Vishal R Chauhan, Sandesh Dev, Michael Pham, Shoutzu Lin, Paul Heidenreich
Journal: Circulation (2014)

Background: Mineralocorticoid Receptor Antagonists (MRA) have been shown to reduce morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction but are associated with hyperkalemia. For this reason the 2009 ACCF/AHA guidelines recommend frequent monitoring of potassium after initiation of an MRA. We sought to evaluate facility-specific characteristics that are associated with adherence to potassium monitoring after MRA initiation. Methods: Using data from 122 Veterans Affairs facilities from 2003 to 2013, we identified patients with a diagnosis of HF who were started on an MRA. The primary outcome was the mean percentage of patients per facility with serum potassium monitoring within 14 days of MRA initiation. Results: There were 176,961 patients identified with a diagnosis of HF who survived at least 14 days after initiation of an MRA. The mean percentage of patients with potassium monitoring per facility was 37% with a standard deviation of 7.2%. Facilities with higher rate...
Abstract 4246: Probing the inhibitor selectivity site of class II PI3KC2β
Authors: Krithika Sundaram, Ian Jennings, Alexandre Arcaro, Philip Thompson
Journal: Cancer Research (2014)

Abstract Ever since their discovery in 1980's, phosphoinositide 3-kinases (PI3Ks) have played a vital role in many intracellular signaling pathways and PI3K inhibitors are prominent targets in drug discovery, especially in cancer. PI3Ks catalyse the phosphorylation of phosphatidylinositol at the 3′-position of the inositol ring and the resulting secondary by-products are implicated in various cellular activities such as cell survival, growth and proliferation. Although class I PI3K has been studied extensively, not much is known about members of class II PI3K. The class II PI3K has gained attention recently as they are believed to be up-regulated in certain types of cancers. The class II PI3Ks consists of three mammalian isoforms: PI3KC2α, PI3KC2β and PI3KC2γ however, as of yet there are no potent, selective inhibitors of class II PI3Ks. We have generated a homology model of PI3KC2β and carried out molecular docking studies of known class I PI3K inhibitors that also show activity against PI3KC2β. Our docking results have revealed that while the overall binding poses are common for the two classes, there are non-conserved residues involved in interactions with these compounds that could be targeted for selectivity. To pursue a screening program based on these concepts, we have expressed and purified active PI3KC2β. Compounds from within our 400 compound PI3K inhibitor library are being screened as our first step to develop novel PI3KC2β-selective inhibitors. In conclusion, identified differences in the catalytic pocket of PI3KC2β, compared to other PI3Ks which may aid discovery of the first novel potent inhibitors of a class II PI3K. Citation Format: Krithika Sundaram, Ian Jennings, Alexandre Arcaro, Philip Thompson. Probing the inhibitor selectivity site of class II PI3KC2β. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4246. doi:10.1158/1538-7445.AM2014-4246
Acrylamide Intake and Breast Cancer Risk in Swedish Women
Authors: Lorelei A. Mucci, Sven Sandin, Katarina Bälter, Hans Olov Adami, Cecilia Magnusson, Elisabete Vainio Weiderpass
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DC-sign, a novel dendritic cell-specific adhesion receptor for ICAM-3 mediates DC-T cell interactions and HIV-1 infection of DC
Authors: T.B.H. Geijtenbeek, R. Torensma, S.J. van Vliet, G.C.F. van Duijnhoven, J. Middel, I.L.M.H.A. Cornelissen, G.J. Adema, H.S.L.M. Nottet, C.G. Figdor, Y. van Kooyk
Journal: Blood (1999)
Vitamin E and Respiratory Tract Infections in Elderly Persons
Authors: Harri Hemilä, Jaakko Kaprio
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal